Beginning in July, UPMC, the Allegheny Health Network and Penn State will join a 2,400-site nationwide study that seeks to treat cancers based on their genetic underpinnings instead of their location in the body.

Though roughly 3,000 cancer patients will be screened for the study, called NCI-MATCH, only those with the genetic abnormalities that match one of the study’s drugs will be enrolled. NCI officials estimate the total enrollment for treatment will be around 1,000 patients. As the trial continues, more genetic abnormalities and their corresponding drugs will be added.

“We have all this new technology where we’re able to sequence the DNA of cancers,” said Adam Brufsky, associate director of clinical investigation for the University of Pittsburgh Cancer Institute. From there, he said, researchers can find the mutations that might respond to specific drugs.

The study is aimed at patients whose standard therapy is no longer working.

Advertise with us

The massive trial is part of President Barack Obama’s Precision Medicine Initiative, announced in this year’s State of the Union Address. That initiative will focus on improving the effectiveness of treatment by tailoring it to a patient’s genetic profile.

Participants will be allowed to continue receiving treatment as long as their cancer stays at steady levels or decreases.

The University of Pittsburgh Cancer Institute was one of the 30 sites nationwide selected by the National Cancer Institute to participate in the study as a lead academic participating site (LAPS). That means it will be responsible for conducting a large portion of the data analysis after results come in, and will handle more patients than non-LAPS institutions, Dr. Brufsky said.

The Allegheny Health Network, which helped design the study with other experts across the nation, and Penn State will also participate in the trial.

While there are other precision medicine studies under way, this study is unique in its scope, said David Parda, chair of the Allegheny Health Network Cancer Institute. Typically, studies only focus on one or two drugs. In comparison, NCI-MATCH will begin by testing 20-25 drugs and will look at 143 genes, said Shannon Puhalla, a co-principal investigator of one of the study’s branches and a physician and breast cancer researcher at the Magee-Womens Hospital of UPMC.

Advertise with us

That’s one reason the study is so large, she said. While some sites may only enroll a couple of patients, a large total is needed to find enough people who have the mutations that can be treated by the selected drugs.

Twenty-five percent of the cancers being studied will be rare cancers, making it even more important to enroll patients at many sites, said Chandra Belani, deputy director of the Penn State Hershey Cancer Institute. The study may end up helping treatments for other diseases as well, he said, if some of the genetic abnormalities being scrutinized end up as driving factors in other diseases.

Several pharmaceutical companies are participating in the trial, including Novartis, Pfizer, Verastem, Boehringer Ingelheim and AstraZeneca.

The study was announced June 1 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Hannah Schwarz: hschwarz@post-gazette.com, 412-263-3772 or on Twitter @hannahrschwarz